Key Highlights

  • Actinogen Medical Ltd (ASX:ACW) are trading at $0.053, up 10.42% on the day.
  • The company's FY26 results confirmed its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial remains on track, with topline results expected in November 2026.
  • Actinogen reported a statutory net loss after tax of $15.4 million for FY26, compared with a $14.7 million loss in the prior year, alongside increased Research and Development spending.
  • The company finished the financial year with $16.7 million in cash and cash equivalents, which it says will fund operations beyond the trial readout into mid-2027.

Actinogen Medical Ltd (ASX:ACW) are trading at $0.053 per share, up 10.42% on the day. The company released its FY26 results and outlook to the Australian Securities Exchange. The announcement provided an update on the progress of the company's lead Alzheimer's disease therapy, Xanamem, and set out the company's financial position for the year ended 30 June 2026.

XanaMIA Trial Remains On Track

According to the announcement, Actinogen's pivotal XanaMIA Phase 2b/3 trial, which is evaluating Xanamem in 247 patients with mild to moderate Alzheimer's disease across Australia and the United States, remained on track during FY26. The company said the trial had received three positive recommendations from its Independent Data Monitoring Committee during the year, including a confidential non-futility review of unblinded efficacy data conducted in January. Patients in the trial receive either Xanamem at 10 milligrams or a placebo once daily for 36 weeks, with the primary endpoint measured using the Clinical Dementia Rating - Sum of Boxes scale. Recruitment for the trial has closed, and topline results are expected in November 2026. Actinogen also began an open-label extension of the trial in March 2026, allowing participants to receive active Xanamem; the company said around 89% of eligible participants moved directly into the extension, with 108 patients on treatment at the time of the update.

Regulatory Progress with FDA and EMA

The company said it had reached common understandings with both the US Food and Drug Administration and the European Medicines Agency during FY26 regarding potential pathways to Marketing approval for Xanamem. This includes agreement on a streamlined design for a further pivotal Alzheimer's disease trial comparing Xanamem 10 milligrams against placebo, which the company plans to begin in 2027.

Financial Position

Actinogen reported a statutory net loss after tax of $15.4 million for FY26, compared with a loss of $14.7 million in the prior corresponding period. Research and development expenditure increased to $19.0 million from $12.3 million, which the company attributed mainly to clinical trial activity. The company finished the financial year with cash and cash equivalents of $16.7 million, which it said provides funding beyond the XanaMIA results and into mid-2027.

Management Commentary

Actinogen CEO Dr Steven Gourlay said FY26 had been a defining year for the company, noting that it had achieved every major objective it had set, including timely enrolment of the pivotal trial, a successful interim efficacy, futility and safety review, and alignment with both the FDA and EMA on relatively streamlined pathways to marketing approval. He said the company's key focus going forward is delivering high-quality pivotal trial results in November while planning subsequent activities needed to progress Xanamem toward regulatory approval.

Conclusion

Actinogen Medical's FY26 results and outlook confirm that its pivotal XanaMIA Alzheimer's disease trial remains on schedule, with topline data due in November 2026 representing the company's next major milestone. The year also saw the company reach regulatory alignment with both the FDA and EMA on potential approval pathways, while its financial position, including $16.7 million in cash at year-end, is intended to fund operations through the trial readout and beyond. Attention now turns to the November data release and the company's subsequent plans for further clinical and regulatory development of Xanamem.